Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification.

DNA adducts are nucleotide bases that have been covalently modified by reactive electrophilic chemical intermediates, and have been extensively researched for their role in mutagenesis and carcinogenesis. However, many DNA adduct measurement techniques have difficulty in the quantification of adducts at realistic human exposure levels. We are using the extremely sensitive analytical technique of accelerator mass spectrometry (AMS) to study adducts either at low dose or directly in humans. AMS is a technique for measuring isotope ratios with high selectivity, attomole sensitivity (10(-18) mol) and precision of 0.5-10%, depending on isotope level and preparation method. This sensitivity and precision is being used to study the dose-response, toxicokinetics, and toxicodynamics of DNA adduct formation and removal following administration of very low doses of chemicals.

[1]  K. Turteltaub,et al.  MeIQx-DNA adduct formation in rodent and human tissues at low doses. , 1997, Mutation research.

[2]  K. Turteltaub,et al.  DNA adducts in model systems and humans , 1993, Journal of cellular biochemistry. Supplement.

[3]  F P Perera,et al.  Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. , 1996, Journal of the National Cancer Institute.

[4]  A. Weston,et al.  Human DNA adduct measurements: state of the art. , 1996, Environmental health perspectives.

[5]  S. Belinsky,et al.  High- to low-dose extrapolation: critical determinants involved in the dose response of carcinogenic substances. , 1987, Environmental health perspectives.

[6]  E C Miller,et al.  Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules , 1981, Cancer.

[7]  F. Kadlubar,et al.  Advantages and limitations of laboratory methods for measurement of carcinogen-DNA adducts for epidemiological studies. , 1992, Toxicology letters.

[8]  K. Turteltaub,et al.  Applications of Accelerator Mass Spectrometry in Toxicology: A Highly Sensitive Tool for Low-Level Isotope Measurements , 1996 .

[9]  R. Taylor,et al.  Radiocarbon After Four Decades , 1992 .

[10]  K. Hemminki,et al.  DNA adducts, mutations and cancer. , 1993, Carcinogenesis.

[11]  K. Turteltaub,et al.  Studies on DNA adduction with heterocyclic amines by accelerator mass spectrometry: a new technique for tracing isotope-labelled DNA adduction. , 1993, IARC scientific publications.

[12]  W. Lutz.  Dose-response relationship and low dose extrapolatioin in chemical carcinogenesis , 1990 .

[13]  H. Gove.  The History of AMS, its Advantages over Decay Counting: Applications and Prospects , 1992 .

[14]  R C Garner,et al.  A preliminary evaluation of accelerator mass spectrometry in the biomedical field. , 1997, Journal of pharmaceutical and biomedical analysis.

[15]  J. Southon,et al.  Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Turteltaub,et al.  Distribution and metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in female rats and their pups at dietary doses. , 1998, Carcinogenesis.

[17]  K. Turteltaub,et al.  Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice. , 1997, Carcinogenesis.

[18]  K. Turteltaub,et al.  Fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in mice at a human dietary equivalent dose. , 1992, Cancer research.

[19]  F. Beland,et al.  Significance of DNA adduct studies in animal models for cancer molecular dosimetry and risk assessment. , 1993, Environmental health perspectives.

[20]  T. Sugimura,et al.  Presence of N2-(deoxyguanosin-8-yl)-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (dG-C8-MeIQx) in human tissues. , 1996, Carcinogenesis.

[21]  K. Turteltaub,et al.  Accelerator mass spectrometry. , 1995, Analytical chemistry.

[22]  K. Turteltaub,et al.  Dose-response studies of MeIQx in rat liver and liver DNA at low doses. , 1995, Carcinogenesis.